Toll Free: 1-888-928-9744

Tuberculosis - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 399 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tuberculosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Tuberculosis - Pipeline Review, H1 2016', provides an overview of the Tuberculosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tuberculosis
- The report reviews pipeline therapeutics for Tuberculosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Tuberculosis therapeutics and enlists all their major and minor projects
- The report assesses Tuberculosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Tuberculosis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Tuberculosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 6 Tuberculosis Overview 7 Therapeutics Development 8 Tuberculosis - Therapeutics under Development by Companies 10 Tuberculosis - Therapeutics under Investigation by Universities/Institutes 15 Tuberculosis - Pipeline Products Glance 18 Tuberculosis - Products under Development by Companies 22 Tuberculosis - Products under Investigation by Universities/Institutes 29 Tuberculosis - Companies Involved in Therapeutics Development 34 Tuberculosis - Therapeutics Assessment 99 Drug Profiles 111 Tuberculosis - Recent Pipeline Updates 337 Tuberculosis - Dormant Projects 356 Tuberculosis - Discontinued Products 366 Tuberculosis - Product Development Milestones 367 Appendix 378
List of Tables
Number of Products under Development for Tuberculosis, H1 2016 28 Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2016 29 Number of Products under Development by Companies, H1 2016 30 Number of Products under Development by Companies, H1 2016 (Contd..1) 31 Number of Products under Development by Companies, H1 2016 (Contd..2) 32 Number of Products under Development by Companies, H1 2016 (Contd..3) 33 Number of Products under Development by Companies, H1 2016 (Contd..4) 34 Number of Products under Investigation by Universities/Institutes, H1 2016 35 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 36 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 37 Comparative Analysis by Late Stage Development, H1 2016 38 Comparative Analysis by Clinical Stage Development, H1 2016 39 Comparative Analysis by Early Stage Development, H1 2016 40 Comparative Analysis by Unknown Stage Development, H1 2016 41 Products under Development by Companies, H1 2016 42 Products under Development by Companies, H1 2016 (Contd..1) 43 Products under Development by Companies, H1 2016 (Contd..2) 44 Products under Development by Companies, H1 2016 (Contd..3) 45 Products under Development by Companies, H1 2016 (Contd..4) 46 Products under Development by Companies, H1 2016 (Contd..5) 47 Products under Development by Companies, H1 2016 (Contd..6) 48 Products under Investigation by Universities/Institutes, H1 2016 49 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 50 Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 51 Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 52 Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 53 Tuberculosis - Pipeline by Abera Bioscience AB, H1 2016 54 Tuberculosis - Pipeline by Achillion Pharmaceuticals, Inc., H1 2016 55 Tuberculosis - Pipeline by Alvogen Korea Co., Ltd., H1 2016 56 Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 57 Tuberculosis - Pipeline by Archivel Farma S.L., H1 2016 58 Tuberculosis - Pipeline by AstraZeneca Plc, H1 2016 59 Tuberculosis - Pipeline by Bayer AG, H1 2016 60 Tuberculosis - Pipeline by BioDiem Ltd, H1 2016 61 Tuberculosis - Pipeline by BioLingus AG, H1 2016 62 Tuberculosis - Pipeline by Biomar Microbial Technologies, H1 2016 63 Tuberculosis - Pipeline by Bioversys AG, H1 2016 64 Tuberculosis - Pipeline by Celgene Corporation, H1 2016 65 Tuberculosis - Pipeline by Cellceutix Corporation, H1 2016 66 Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2016 67 Tuberculosis - Pipeline by Dafra Pharma International Ltd., H1 2016 68 Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 69 Tuberculosis - Pipeline by Eisai Co., Ltd., H1 2016 70 Tuberculosis - Pipeline by Eli Lilly and Company, H1 2016 71 Tuberculosis - Pipeline by Ensol Biosciences Inc., H1 2016 72 Tuberculosis - Pipeline by EpiVax, Inc., H1 2016 73 Tuberculosis - Pipeline by FIT Biotech Oy, H1 2016 74 Tuberculosis - Pipeline by GangaGen Inc., H1 2016 75 Tuberculosis - Pipeline by GlaxoSmithKline Plc, H1 2016 76 Tuberculosis - Pipeline by Globeimmune, Inc., H1 2016 77 Tuberculosis - Pipeline by Hager Biosciences, LLC, H1 2016 78 Tuberculosis - Pipeline by Hsiri Therapeutics, LLC, H1 2016 79 Tuberculosis - Pipeline by Imaxio SA, H1 2016 80 Tuberculosis - Pipeline by Immunitor, Inc., H1 2016 81 Tuberculosis - Pipeline by ImmunoBiology Limited, H1 2016 82 Tuberculosis - Pipeline by Immunovaccine, Inc., H1 2016 83 Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 84 Tuberculosis - Pipeline by Johnson & Johnson, H1 2016 85 Tuberculosis - Pipeline by Lipotek Pty Ltd., H1 2016 86 Tuberculosis - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 87 Tuberculosis - Pipeline by Microbion Corporation, H1 2016 88 Tuberculosis - Pipeline by Microbiotix, Inc., H1 2016 89 Tuberculosis - Pipeline by NEARMEDIC PLUS, Ltd, H1 2016 90 Tuberculosis - Pipeline by Novartis AG, H1 2016 91 Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2016 92 Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 93 Tuberculosis - Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H1 2016 94 Tuberculosis - Pipeline by Prokarium Limited, H1 2016 95 Tuberculosis - Pipeline by QureTech Bio AB, H1 2016 96 Tuberculosis - Pipeline by Recce Limited, H1 2016 97 Tuberculosis - Pipeline by Rodos BioTarget GmbH, H1 2016 98 Tuberculosis - Pipeline by Sanofi, H1 2016 99 Tuberculosis - Pipeline by Sanofi Pasteur SA, H1 2016 100 Tuberculosis - Pipeline by Sarepta Therapeutics, Inc., H1 2016 101 Tuberculosis - Pipeline by SEEK Group, H1 2016 102 Tuberculosis - Pipeline by Sequella, Inc., H1 2016 103 Tuberculosis - Pipeline by Shionogi & Co., Ltd., H1 2016 104 Tuberculosis - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 105 Tuberculosis - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 106 Tuberculosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 107 Tuberculosis - Pipeline by TetraLogic Pharmaceuticals, H1 2016 108 Tuberculosis - Pipeline by Theravectys SA, H1 2016 109 Tuberculosis - Pipeline by Tomegavax, Inc., H1 2016 110 Tuberculosis - Pipeline by Transgene SA, H1 2016 111 Tuberculosis - Pipeline by TVAX Biomedical, Inc., H1 2016 112 Tuberculosis - Pipeline by Univalue Valorizacion, S.L., H1 2016 113 Tuberculosis - Pipeline by Vaccibody AS, H1 2016 114 Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H1 2016 115 Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2016 116 Tuberculosis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 117 Tuberculosis - Pipeline by Vichem Chemie Research Ltd., H1 2016 118 Assessment by Monotherapy Products, H1 2016 119 Assessment by Combination Products, H1 2016 120 Number of Products by Stage and Target, H1 2016 122 Number of Products by Stage and Mechanism of Action, H1 2016 125 Number of Products by Stage and Route of Administration, H1 2016 128 Number of Products by Stage and Molecule Type, H1 2016 130 Tuberculosis Therapeutics - Recent Pipeline Updates, H1 2016 357 Tuberculosis - Dormant Projects, H1 2016 376 Tuberculosis - Dormant Projects (Contd..1), H1 2016 377 Tuberculosis - Dormant Projects (Contd..2), H1 2016 378 Tuberculosis - Dormant Projects (Contd..3), H1 2016 379 Tuberculosis - Dormant Projects (Contd..4), H1 2016 380 Tuberculosis - Dormant Projects (Contd..5), H1 2016 381 Tuberculosis - Dormant Projects (Contd..6), H1 2016 382 Tuberculosis - Dormant Projects (Contd..7), H1 2016 383 Tuberculosis - Dormant Projects (Contd..8), H1 2016 384 Tuberculosis - Dormant Projects (Contd..9), H1 2016 385 Tuberculosis - Discontinued Products, H1 2016 386


List of Figures
Number of Products under Development for Tuberculosis, H1 2016 28 Number of Products under Development for Tuberculosis - Comparative Analysis, H1 2016 29 Number of Products under Development by Companies, H1 2016 30 Number of Products under Investigation by Universities/Institutes, H1 2016 35 Comparative Analysis by Late Stage Development, H1 2016 38 Comparative Analysis by Clinical Stage Development, H1 2016 39 Comparative Analysis by Early Stage Products, H1 2016 40 Assessment by Monotherapy Products, H1 2016 119 Assessment by Combination Products, H1 2016 120 Number of Products by Top 10 Targets, H1 2016 121 Number of Products by Stage and Top 10 Targets, H1 2016 121 Number of Products by Top 10 Mechanism of Actions, H1 2016 124 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 124 Number of Products by Top 10 Routes of Administration, H1 2016 127 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 127 Number of Products by Top 10 Molecule Types, H1 2016 129 Number of Products by Stage and Top 10 Molecule Types, H1 2016 129

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify